Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Follow-Up Questions
Who is the CEO of Biodexa Pharmaceuticals PLC?
Mr. Stephen Stamp is the Chief Executive Officer of Biodexa Pharmaceuticals PLC, joining the firm since 2019.
What is the price performance of BDRX stock?
The current price of BDRX is $5.62, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Biodexa Pharmaceuticals PLC?
Biodexa Pharmaceuticals PLC belongs to Biotechnology industry and the sector is Health Care
What is Biodexa Pharmaceuticals PLC market cap?
Biodexa Pharmaceuticals PLC's current market cap is $3.4M
Is Biodexa Pharmaceuticals PLC a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Biodexa Pharmaceuticals PLC, including 3 strong buy, 3 buy, 1 hold, 0 sell, and 3 strong sell
